Erytech Pharma (ERYP) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Erytech Pharma (NASDAQ:ERYP) from a buy rating to a sell rating in a research report report published on Tuesday morning, reports.

According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “

Separately, ValuEngine downgraded shares of Erytech Pharma from a sell rating to a strong sell rating in a research report on Wednesday, April 3rd.

Shares of ERYP traded down $0.45 during midday trading on Tuesday, hitting $7.06. The company had a trading volume of 5 shares, compared to its average volume of 2,308. The company has a market capitalization of $134.71 million, a P/E ratio of 2.89 and a beta of 1.70. Erytech Pharma has a 52 week low of $5.45 and a 52 week high of $20.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.19 and a current ratio of 7.26.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

Featured Article: Strike Price

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with's FREE daily email newsletter.